| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by date.
Page 5: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1201 | 0 | 0 | 1168 2001 OCT 23 CIRCULATION 104(17):566-566 Kishan CV; Saucedo JF; Fahdi I; Gaddam V; Razek H; Bissett JK; Anaissie E; Barlogie B; Mehta JL High dose thalidomide is associated with symptomatic bradycardia | 0 | 0 |
| 1202 | 31 | 67 | 1160 2001 NOV 1 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 7 | 14 |
| 1203 | 10 | 15 | 1229 2001 NOV 1 JOURNAL OF INFECTIOUS DISEASES 184(9):1192-1196 Hanekom WA; Hughes J; Haslett PAJ; Apolles P; Ganiso V; Allin R; Goddard E; Hussey GD; Kaplan G The immunomodulatory effects of thalidomide on human immunodeficiency virus-infected children | 3 | 3 |
| 1204 | 3 | 5 | 1078 2001 NOV 12 ARCHIVES OF INTERNAL MEDICINE 161(20):2502-2503 Rajkumar SV; Fonseca R; Witzig TE Complete resolution of reflex sympathetic dystrophy with thalidomide treatment | 3 | 4 |
| 1205 | 8 | 12 | 1066 2001 NOV [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 96(11):3207-3209 Raufman JP; Lamps LW Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C | 0 | 0 |
| 1206 | 58 | 116 | 1072 2001 NOV [15] ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
| 1207 | 2 | 12 | 1155 2001 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 115(2):313-315 Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M Thalidomide in agnogenic and secondary myelofibrosis | 12 | 17 |
| 1208 | 3 | 8 | 1156 2001 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 115(2):484-485 Biagi JJ; Prince HM Thalidomide is effective for extramedullary relapse of multiple myeloma postallogeneic bone marrow transplantation | 1 | 1 |
| 1209 | 36 | 60 | 1164 2001 NOV [15] CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
| 1210 | 1 | 2 | 1165 2001 NOV [15] CHEMISTRY IN BRITAIN 37(11):38-40 Stephens T Reinventing thalidomide | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1211 | 7 | 25 | 1172 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3311-3313 Onn A; Tseng JE; Herbst RS Thalidomide, cyclooxygenase-2, and angiogenesis: Potential for therapy | 2 | 11 |
| 1212 | 12 | 56 | 1173 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 22 | 32 |
| 1213 | 0 | 0 | 1174 2001 NOV [15] CLINICAL CANCER RESEARCH 7(11):3666S-3667S Hsu C; Chen C; Chen L; Wu C; Hsieh F; Cheng A Use of thalidomide in the treatment of advanced hepatocellular carcinoma (HCC): With emphasis on using power Doppler sonography to evaluate the vascularity of the tumor and its correlation with tumor response. | 0 | 0 |
| 1214 | 1 | 1 | 1187 2001 NOV [15] EUROPEAN JOURNAL OF CANCER 37(16):1966-1966 [Anon] Thalidomide is back | 0 | 0 |
| 1215 | 12 | 24 | 1214 2001 NOV [15] INTERNATIONAL JOURNAL OF CLINICAL PRACTICE 55(9):627-631 Diggle GE Thalidomide: 40 years on | 7 | 10 |
| 1216 | 0 | 0 | 1243 2001 NOV [15] MOLECULAR BIOLOGY OF THE CELL 12:23A-23A Ezell TN Apoptotic cell death induced by low doses of the tumor necrosis alpha inhibitor, thalidomide in human T leukemic cells | 0 | 0 |
| 1217 | 2 | 10 | 1261 2001 NOV-DEC [NOV 15] POLISH JOURNAL OF PHARMACOLOGY 53(6):709-713 Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M Influence of thalidomide on Bcl(2) expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients | 0 | 0 |
| 1218 | 0 | 0 | 1264 2001 NOV [15] RADIOLOGY 221:387-387 Faria SC; Charnsangavej C; Sawaf Y; Hess KR; Tamm EP; Lee T CT quantification of antiangiogenic effects of thalidomide | 0 | 0 |
| 1219 | 0 | 0 | 1097 2001 NOV 16 BLOOD 98(11):52B-52B Anders O; Plath F; Emmrich J; Freund M Complete remission of therapy-resistant angiodysplasia of the stomach in myelodysplastic syndrome following thalidomide. | 0 | 0 |
| 1220 | 0 | 0 | 1098 2001 NOV 16 BLOOD 98(11):52B-52B Arkel YS; Ku DHW; Le P Effect of thalidomide on tissue factor activity in monocytic and endothelial cell lines, and relationship to tumor necrosis factor-alpha (TNF). | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1221 | 0 | 0 | 1099 2001 NOV 16 BLOOD 98(11):161A-162A Zangari M; Siegel E; Anaissie E; Saghafifar F; Morris C; Fink L; Barlogie B; Tricot G Risk factors for deep vein thrombosis (DVT) in a large group of myeloma patients (pts) treated with thalidomide (Thal): The Arkansas experience. | 0 | 4 |
| 1222 | 0 | 0 | 1100 2001 NOV 16 BLOOD 98(11):162A-162A Palumbo A; Giaccone L; Bringhen S; Cavallo F; Falco P; Rus C; Bertola A; Pileri A; Boccadoro M Low dose thalidomide and dexamethasone are as effective as oral melphalan and prednisone in refractory and relapsed myeloma patients. | 0 | 4 |
| 1223 | 0 | 0 | 1101 2001 NOV 16 BLOOD 98(11):162A-162A Kakimoto T; Hattori Y; Okamoto S; Sato N; Yamaguchi M; Morita K; Yamada T; Takayama N; Shimada N; Tanigawara Y; Ikeda Y Clinical significance of serial monitoring of plasma concentration of thalidomide and angiogenic growth factors in patients with refractory myeloma. | 0 | 1 |
| 1224 | 0 | 0 | 1102 2001 NOV 16 BLOOD 98(11):162A-162A Wechalekar AD; Sutton D; Voralia M; Stewart AK; Chen CI Intermediate dose thalidomide (200mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. | 0 | 5 |
| 1225 | 0 | 0 | 1103 2001 NOV 16 BLOOD 98(11):162A-163A Rajkumar SV; Dispenzieri A; Lacy M; Geyer S; Iturria N; Fonseca R; Hayman SR; Lust JA; Kyle R; Greipp PR; Gertz MA; Witzig TE Response rate and durablity of response with thalidomide therapy for relapsed multiple myeloma (MM). | 0 | 4 |
| 1226 | 0 | 0 | 1104 2001 NOV 16 BLOOD 98(11):163A-163A Durie BGM; Stepan DE Low dose thalidomide alone and in combination: Long term follow-up. | 0 | 6 |
| 1227 | 0 | 0 | 1105 2001 NOV 16 BLOOD 98(11):163A-163A Tosi P; Zamagni E; Cellini C; Cangini D; Tura S; Baccarani M; Cavo M Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractor multiple myeloma. | 0 | 3 |
| 1228 | 0 | 0 | 1106 2001 NOV 16 BLOOD 98(11):163A-163A Alexanian R; Weber DM; Giralt S; Delasalle KB Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy. | 0 | 2 |
| 1229 | 0 | 0 | 1107 2001 NOV 16 BLOOD 98(11):163A-163A Neben K; Moehler TM; Benner A; Kraemer A; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM). | 0 | 0 |
| 1230 | 0 | 0 | 1108 2001 NOV 16 BLOOD 98(11):163A-163A Grosbois B; Bellissant E; Moreau P; Attal M; Zerbib R Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM). A prospective study of 120 patients. | 0 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1231 | 0 | 0 | 1109 2001 NOV 16 BLOOD 98(11):164A-164A Dimopoulos M; Panayiotidis P; Grigoraki V; Poziopoulos C; Xilouri I; Kiamouris C; Tassidou A; Gika D; Stefanoudaki K; Anagnostopoulos N; Anagnostou D Oral hyperfractionated cyclophosphamide and intermittent thalidomide-dexamethasone for previously treated patients with multiple myeloma. | 0 | 7 |
| 1232 | 0 | 0 | 1110 2001 NOV 16 BLOOD 98(11):164A-164A Seldin DC; Choufani E; Skinner M; Wright DG; Dember L; Weisman J; Fennessey S; Finn K; Sanchorawala V A phase I/II trial of thalidomide for patients with AL amyloidosis. | 0 | 1 |
| 1233 | 0 | 0 | 1111 2001 NOV 16 BLOOD 98(11):182B-182B Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Yalcin A Terminal differentiation and apoptosis of myeloid leukemia induced by thalidomide and rhGM-CSF combination. | 0 | 0 |
| 1234 | 0 | 0 | 1112 2001 NOV 16 BLOOD 98(11):215B-215B Manson SD; Venugopal P; Gregory SA; Raza A; Sivaraman S; Preisler H Treatment of relapsed/refractory acute myeloid leukemia (AML) with thalidomide as a single agent: Clinical and biologic responses. | 0 | 0 |
| 1235 | 0 | 0 | 1113 2001 NOV 16 BLOOD 98(11):222B-222B Sivaraman S; Venugopal P; Hu WY; Gladstone B; Galili N; Nair A; Manjali J; Mogongwa A; Zhao HP; Manson S; Preisler H Effect of thalidomide as a single agent on serum cytokine levels in patients with relapsed acute myeloid leukemia. | 0 | 0 |
| 1236 | 0 | 0 | 1114 2001 NOV 16 BLOOD 98(11):246B-246B Pro B; Younes A; Albitar M; Hagemeister FB; Rodriguez MA; McLaughlin P; Clemons M; Samaniego F; Cabanillas F Phase II study of thalidomide in patients with recurrent Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL). | 0 | 0 |
| 1237 | 0 | 0 | 1115 2001 NOV 16 BLOOD 98(11):271B-271B Fabbri A; Biscardi M; Innocenti F; Balestri F; Gavazzi S; Bellesi G; Grossi A Thalidomide in combination with amifostine in the treatment of MDS: Evaluation of clinical and laboratory findings. | 0 | 0 |
| 1238 | 0 | 0 | 1116 2001 NOV 16 BLOOD 98(11):273B-273B Raza A; Lisak L; Dutt D; Dean L; Fantroy L; Syed E; Gezer S; Hsu WT; Goldberg C; Loew J; Venugopal P Combination of thalidomide with pentoxifylline, ciprofloxacin, and dexamethasone (PCD) in patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1239 | 0 | 0 | 1117 2001 NOV 16 BLOOD 98(11):273B-274B Raza A; Dutt D; Lisak L; Dean L; Fantroy L; Gezer S; Syed E; Goldberg C; Loew J; Hsu WT; Venugopal P Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS). | 0 | 0 |
| 1240 | 0 | 0 | 1118 2001 NOV 16 BLOOD 98(11):296B-297B Dmoszynska A; Rolinski J; Bojarska-Junak A; Manko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M; Domanski D Influence of thalidomide on bcl-2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow lymphocyte subsets of multiple myeloma patients. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1241 | 0 | 0 | 1119 2001 NOV 16 BLOOD 98(11):307B-307B Ahmad I; Alam AR; Hahn T; Becker J; Chanan-Khan AA; Czuczman M; Bernstein S; Bernstein Z; McCarthy P Thalidomide plus VAD (vincristine, doxorabicin and dexamethasone) salvage therapy for VAD-refractory multiple myeloma, prior to autologous peripheral blood stem cell transplant (PBSCT). | 0 | 0 |
| 1242 | 0 | 0 | 1120 2001 NOV 16 BLOOD 98(11):307B-307B Bibas M; Andriani A; Ferrari A; Montanaro M; Niscola G; Recine U; Chierichini A Thalidomide treatment for relapsed/refractory multiple myeloma: A retrospective multicenter study. | 0 | 0 |
| 1243 | 0 | 0 | 1121 2001 NOV 16 BLOOD 98(11):307B-307B Alegre A; Macias GR; Granda A; Golbano N; Martinez E; Alaez C; Blazquez C; Gongora E; Cannata J; Sanchez-Godoy P; Martinez-Chamorro C; Arranz R; de Soria VGG; Figuera A; Arranz E; Fernandez-Ranada JM Thalidomide as rescue treatment of relapses after haematopoietic transplantation in multiple myeloma. | 0 | 0 |
| 1244 | 0 | 0 | 1122 2001 NOV 16 BLOOD 98(11):308B-308B Grosbois B; Bellissant E; Muret E; Voillat L; Zerbib R Measurement of seric thalidomide (Thal) level in patients treated for advanced multiple myeloma (MM). | 0 | 2 |
| 1245 | 0 | 0 | 1123 2001 NOV 16 BLOOD 98(11):309B-309B Kasper B; Moehler TM; Neben K; Ho AD; Goldschmidt H Response to a combination therapy of thalidomide and Pegintron (R) in patients with progressive multiple myeloma (MM). | 0 | 1 |
| 1246 | 0 | 0 | 1124 2001 NOV 16 BLOOD 98(11):310B-310B Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: Implications for multiple myeloma therapy. | 0 | 0 |
| 1247 | 0 | 0 | 1125 2001 NOV 16 BLOOD 98(11):311B-311B Offidani M; Mele A; Marconi M; Corvatta L; Candela M; Pieroni S; Malerba L; Rupoli S; Olivieri A; Leoni P Thalidomide plus melphalan in relapsed-refractory multiple myeloma. | 0 | 1 |
| 1248 | 0 | 0 | 1126 2001 NOV 16 BLOOD 98(11):311B-311B Avalos JS; Barazzutti L; Korin J; Kusminsky G; Ferro H; Tavella O; Foncuberta M; Tartas N Thalidomide and cranial nerves neuropathies. | 0 | 0 |
| 1249 | 0 | 0 | 1127 2001 NOV 16 BLOOD 98(11):313B-313B Womeldorph JL; Myhand RC; Monahan BP Reversible acute renal failure following initiation of thalidomide therapy in a patient with relapsed multiple myeloma. | 0 | 0 |
| 1250 | 0 | 0 | 1128 2001 NOV 16 BLOOD 98(11):351A-352A Alvi S; Shaher A; Shaikh M; Anthwal S; Siddiqi F; Akhtar A; Ashraf H; Meagher R; Mundle S; Shetty V; Goldberg C; Galili N; Borok RZ; Raza A MDS patients with hematological response to thalidomide show enhanced in vitro growth potential. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1251 | 0 | 0 | 1129 2001 NOV 16 BLOOD 98(11):352A-352A Alvi S; Shaikh M; Anthwal S; Shaher A; Tamoseviciene D; Novick A; Reddy P; Allampallam K; Hsu WT; Galili N; Borok RZ; Raza A Cytogenetic and clonal profile of myelodysplastic syndromes (MDS) patients treated with thalidomide. | 0 | 0 |
| 1252 | 0 | 0 | 1130 2001 NOV 16 BLOOD 98(11):353A-354A Baker AF; Bellamy WT; Glinsmann-Gibson BJ; Heaton R; Buresh A; Grogan TM; List AF Biological response to thalidomide in remitting patients with myelodysplastic syndrome (MDS): Evidence for induction of neoplastic vascular endothelial growth factor (VEGF) resistance. | 0 | 0 |
| 1253 | 0 | 0 | 1131 2001 NOV 16 BLOOD 98(11):365B-365B Game M; Coso D; Sturgeon J; Crump M; Keating A Thalidomide and low dose vinblastine as palliative therapy for patients relapsing after autotransplant for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). | 0 | 1 |
| 1254 | 0 | 0 | 1132 2001 NOV 16 BLOOD 98(11):373A-374A Uziel O; Shapira A; Radnay J; Lahav M; Lishner M Thalidomide downregulates transcript levels of GC-rich promoter genes in multiple myeloma. | 0 | 0 |
| 1255 | 0 | 0 | 1133 2001 NOV 16 BLOOD 98(11):395B-395B Moehler TM; Neben K; Kasper B; Kordelas L; Egerer G; Goerner M; Ho AD; Goldschmidt H Thalidomide plus CED chemotherapy as remission induction regimen for poor prognosis multiple myeloma patients before autologous or allogeneic stem cell transplantation. | 0 | 0 |
| 1256 | 0 | 0 | 1134 2001 NOV 16 BLOOD 98(11):622A-622A Musto P; Falcone A; Bodenizza C; Sanpaolo G; Matera R; Bisceglia M; Carella AM Thalidomide (THAL) significantly improves anemia in selected transfusion-dependent patients with myelodysplastic syndromes (MDS): Relationship to serum and marrow levels of angiogenetic growth factors (AGF). | 0 | 3 |
| 1257 | 0 | 0 | 1135 2001 NOV 16 BLOOD 98(11):627A-627A Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt R; Geyer GM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia (MMM). | 0 | 1 |
| 1258 | 0 | 0 | 1136 2001 NOV 16 BLOOD 98(11):685A-685A Somlo G; Yamamoto N; Sarah C; O'Donnell M; Snyder D; Sahebi F; Kogut N; Spielberger R; Molina A; Parker P; Popplewell L; Fung H; Rodriguez R; Stein A; Krishnan A; Chow W; Lopez F; Forman S Tandem cycle high-dose melphalan and intravenous busulfan/cytoxan with peripheral blood progenitor cell rescue (PBPC) followed by interferon alpha-2 (IF) with, or without thalidomide (Thal) for multiple myeloma. High complete response rate and moderate toxicities. | 0 | 1 |
| 1259 | 0 | 0 | 1137 2001 NOV 16 BLOOD 98(11):775A-775A Richardson PG; Schlossman RL; Hideshima T; Davies F; LeBlanc R; Catley L; Doss D; Kelly KA; McKenney M; Mechlowicz J; Freeman A; Deocampo R; Rich R; Ryoo J; Chauhan D; Munshi N; Weller E; Thomas S; Zeldis J; Anderson KC A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 0 | 10 |
| 1260 | 0 | 0 | 1138 2001 NOV 16 BLOOD 98(11):775A-775A Mitsiades N; Mitsiades CS; Poulaki V; Akiyama M; Tai YT; Lin BK; Hayashi T; Catley L; Hideshima T; Chauhan D; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: Therapeutic implications. | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1261 | 0 | 0 | 1139 2001 NOV 16 BLOOD 98(11):849A-849A Rajkumar SV; Hayman SR; Gertz MA; Dispenzieri A; Lacy M; Greipp PR; Geyer S; Itturia N; Fonseca R; Lust JA; Kyle R; Witzig TE Combination therapy with thalidomide plus dexamethasone (THAL/DEX) for newly diagnosed myeloma (MM). | 0 | 5 |
| 1262 | 0 | 0 | 1140 2001 NOV 16 BLOOD 98(11):849A-849A Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Goldschmidt H Genetic polymorphism in the tumor necrosis factor-alpha locus influences the outcome to thalidomide therapy in relapsed and refractory multiple myeloma (MM). | 0 | 1 |
| 1263 | 0 | 0 | 1141 2001 NOV 16 BLOOD 98(11):863A-863A Bennett CL; Schumok GT; Kwaan HC; Raisch DW High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered. | 0 | 3 |
| 1264 | 99 | 191 | 1087 2001 20011127-04:23:06 [NOV 27] BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 7 | 14 |
| 1265 | 0 | 0 | 1191 2001 20011129-03:40:35 [NOV 29] FREE RADICAL BIOLOGY AND MEDICINE 31:S54-S54 Hansen JM; Gong SG; Harris C Thalidomide (TD) depletes glutathione and alters gene expression in the developing limb. | 0 | 0 |
| 1266 | 3 | 19 | 1142 2001 DEC 15 BLOOD 98(13):3846-3848 Moehler TM; Neben K; Benner A; Egerer G; Krasniqi F; Ho AD; Goldschmidt H Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy | 14 | 22 |
| 1267 | 10 | 38 | 1145 2001 DEC [15] BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
| 1268 | 3 | 12 | 1157 2001 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 115(3):605-608 Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion | 20 | 30 |
| 1269 | 8 | 53 | 1158 2001 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 14 | 23 |
| 1270 | 14 | 63 | 1181 2001 DEC [15] DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1271 | 37 | 44 | 1218 2001 DEC [15] JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
| 1272 | 6 | 6 | 1236 2001 DEC [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 3 | 6 |
| 1273 | 7 | 18 | 1270 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):577-582 Barlogie B; Tricot G; Anaissie E Thalidomide in the management of multiple myeloma | 10 | 17 |
| 1274 | 7 | 21 | 1271 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):583-587 Kyle RA; Rajkumar SV Therapeutic application of thalidomide in multiple myeloma | 5 | 9 |
| 1275 | 6 | 18 | 1272 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
| 1276 | 12 | 25 | 1273 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):593-596 Desikan RK; Jagannath S Therapeutic dilemmas with thalidomide in multiple myeloma: Case discussions | 2 | 2 |
| 1277 | 19 | 47 | 1274 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
| 1278 | 15 | 17 | 1275 2001 DEC [15] SEMINARS IN ONCOLOGY 28(6):602-606 Stirling D Thalidomide: A novel template for anticancer drugs | 8 | 13 |
| 1279 | 6 | 20 | 1483 2002 JAN 1 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 22 | 36 |
| 1280 | 4 | 5 | 1417 2002 20030108-18:15:13 [JAN 08] CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418 Jin SH; Il Kim T; Han DS; Shin SK; Kim WH Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1281 | 9 | 23 | 1531 2002 20030114-02:36:42 [JAN 14] MEDICAL ONCOLOGY 19(4):219-226 Srkalovic G; Elson P; Trebisky B; Karam MA; Hussein MA Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma | 1 | 2 |
| 1282 | 13 | 14 | 1443 2002 JAN-FEB [JAN 15] EUROPEAN JOURNAL OF DERMATOLOGY 12(1):63-65 Frances C; El Khoury S; Gompel A; Becherel PA; Chosidow O; Piette JC Transient secondary amenorrhea in women treated by thalidomide | 1 | 2 |
| 1283 | 7 | 20 | 1504 2002 JAN [15] JOURNAL OF PEDIATRICS 140(1):125-127 Lehman TJA; Striegel KH; Onel KB Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis | 4 | 8 |
| 1284 | 4 | 40 | 1505 2002 JAN 15 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
| 1285 | 7 | 22 | 1517 2002 JAN [15] LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 15 | 26 |
| 1286 | 5 | 24 | 1519 2002 JAN [15] LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 1287 | 4 | 11 | 1535 2002 JAN [15] OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
| 1288 | 1 | 1 | 1536 2002 JAN [15] ONCOLOGY-NEW YORK 16(1):21-22 Kurstin R Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease | 1 | 1 |
| 1289 | 18 | 28 | 1537 2002 JAN [15] ONCOLOGY-NEW YORK 16(1):22-24 Richardson P; Anderson K Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease - Drs. Paul Richardson and Kenneth Anderson respond | 0 | 0 |
| 1290 | 6 | 24 | 1543 2002 JAN [15] PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1291 | 18 | 36 | 1317 2002 FEB 1 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 11 | 25 |
| 1292 | 16 | 24 | 1480 2002 FEB 5 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 767(1):145-151 Teo SK; Chandula RS; Harden JL; Stirling DI; Thomas SD Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry | 4 | 5 |
| 1293 | 12 | 26 | 1306 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):1-3 Mathe G Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system | 0 | 0 |
| 1294 | 53 | 61 | 1307 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 17 | 21 |
| 1295 | 17 | 42 | 1308 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
| 1296 | 15 | 82 | 1309 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
| 1297 | 17 | 48 | 1310 2002 FEB [15] BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 11 |
| 1298 | 0 | 0 | 1431 2002 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 71(2):P83-P83 Lakhani N; Gordon S; Figg W; Dionne R Absorption and adverse effects of topical thalidomide. | 0 | 0 |
| 1299 | 0 | 0 | 1451 2002 FEB [15] FERTILITY AND STERILITY 77(2):S28-S28 Zhong S; Shen K; Lang J The effects of thalidomide on interleukin-6 and vascular endothelial growth factor expression of endometrial stromal cell in vitro. | 0 | 0 |
| 1300 | 13 | 36 | 1458 2002 FEB [15] GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1301 | 1 | 8 | 1465 2002 FEB [15] HAUTARZT 53(2):150-150 Ochsendorf F; Kaufman R Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 0 | 0 |
| 1302 | 2 | 2 | 1466 2002 FEB [15] HAUTARZT 53(2):150-151 Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis - Statement | 0 | 0 |
| 1303 | 2 | 4 | 1484 2002 FEB 15 JOURNAL OF CLINICAL ONCOLOGY 20(4):1147-1149 Abramson N; Stokes PK; Luke M; Marks AR; Harris JM Ovarian and papillary-serous peritoneal carcinoma: Pilot study with thalidomide | 0 | 3 |
| 1304 | 13 | 25 | 1492 2002 FEB [15] JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(2):135-139 Bariol C; Meagher AP; Vickers CR; Byrnes DJ; Edwards PD; Hing M; Wettstein AR; Field A Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease | 8 | 13 |
| 1305 | 7 | 8 | 1520 2002 FEB [15] LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
| 1306 | 4 | 26 | 1521 2002 FEB [15] LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 1307 | 22 | 34 | 1554 2002 FEB [15] THERAPEUTIC DRUG MONITORING 24(1):104-110 Price DK; Ando Y; Kruger EA; Weiss M; Figg WD 5 '-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis | 9 | 10 |
| 1308 | 4 | 4 | 1485 2002 MAR 1 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 8 | 12 |
| 1309 | 27 | 34 | 1297 2002 MAR [15] ANNALS OF PHARMACOTHERAPY 36(3):521-525 Bessmertny O; Pham T Thalidomide use in pediatric patients | 1 | 2 |
| 1310 | 26 | 91 | 1313 2002 MAR [15] BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 8 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1311 | 0 | 0 | 1391 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S100-S100 Mohty M; Stoppa A; Blaise D; Isnardon D; Gastaut J; Olive D; Gaugler B Differential regulation of dendritic cell function by the Immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1312 | 0 | 0 | 1392 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S104-S104 Patriarca F; Fill C; Sperotto A; Damiani D; Zaja F; Cerno M; Fanin R Thalidomide overcomes VAD chemoresistance and allows PBSC collection in 3 multiple myeloma patients | 0 | 0 |
| 1313 | 0 | 0 | 1393 2002 MAR [15] BONE MARROW TRANSPLANTATION 29:S255-S256 Dagan L; Ovadia R; Taou D; Bar L The introduction of thalidomide (T) in BMT programs for patients with multiple myeloma (MM): encouraging results and a challenge for nursing team | 0 | 0 |
| 1314 | 12 | 49 | 1429 2002 MAR [15] CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 8 |
| 1315 | 18 | 23 | 1459 2002 MAR [15] HAEMATOLOGICA 87(3):233-234 Tosi P; Cavo M Thalidomide in multiple myeloma: state of art | 3 | 4 |
| 1316 | 4 | 7 | 1460 2002 MAR [15] HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| 1317 | 10 | 21 | 1491 2002 MAR-APR [MAR 15] JOURNAL OF COMBINATORIAL CHEMISTRY 4(2):149-153 Xiao ZL; Schaefer K; Firestine S; Li PK Solid-phase synthesis of thalidomide and its analogues | 0 | 4 |
| 1318 | 10 | 18 | 1493 2002 MAR [15] JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 17(3):233-235 Selby W Thalidomide in inflammatory bowel disease: Too little, too soon | 0 | 0 |
| 1319 | 37 | 67 | 1494 2002 MAR 15 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 25 |
| 1320 | 10 | 40 | 1507 2002 MAR [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1321 | 1 | 4 | 1538 2002 MAR [15] ONCOLOGY-NEW YORK 16(3):276-+ Phuphanich S Recurrent multicentric glioblastoma multiforme responds to thalidomide and chemotherapy | 0 | 0 |
| 1322 | 5 | 25 | 1548 2002 MAR [15] RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
| 1323 | 0 | 0 | 1438 2002 20030325-03:44:42 [MAR 25] DRUG METABOLISM REVIEWS 34:148-148 Zhou SF; Li Y; Kestell P; Paxton JW Preliminary study of thalidomide transport by the human intestinal cell line Caco-2 | 0 | 0 |
| 1324 | 63 | 112 | 1298 2002 20020329-01:42:11 [MAR 29] ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 23 | 36 |
| 1325 | 5 | 16 | 1289 2002 APR 1 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 9 | 10 |
| 1326 | 8 | 30 | 1315 2002 APR 8 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 12(7):1043-1046 Noguchi T; Shimazawa R; Nagasawa K; Hashimoto Y Thalidomide and its analogues as cyclooxygenase inhibitors | 12 | 15 |
| 1327 | 6 | 6 | 1436 2002 APR 12 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
| 1328 | 8 | 23 | 1446 2002 20030414-19:22:57 [APR 14] EUROPEAN JOURNAL OF SURGERY 168(11):641-645 Mall JW; Schwenk W; Philipp AW; Muller JM; Pollmann C Thalidomide given intraperitoneally reduces the number of postoperative adhesions after large bowel resection in rabbits | 0 | 0 |
| 1329 | 9 | 24 | 1282 2002 APR [15] AKTUELLE NEUROLOGIE 29(3):149-152 Vogt T; Nill M; Hundsberger T Thalidomide neuropathy | 0 | 0 |
| 1330 | 0 | 21 | 1292 2002 APR [15] ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY 88(4):421-424 Medeiros M; Araujo MI; Guimaraes NS; Freitas LAR; Silva TMC; Carvalho EM Therapeutic response to thalidomide in Melkersson-Rosenthal syndrome: a case report | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1331 | 11 | 19 | 1316 2002 APR [15] BJU INTERNATIONAL 89(6):591-595 Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide | 1 | 4 |
| 1332 | 9 | 19 | 1394 2002 APR [15] BONE MARROW TRANSPLANTATION 29(7):577-580 Ahmad I; Islam T; Chanan-Khan A; Hahn T; Wentling D; Becker JL; McCarthy PL; Alam AR Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 6 | 7 |
| 1333 | 0 | 0 | 1453 2002 APR [15] GASTROENTEROLOGY 122(4):A194-A194 Bauditz J; Wedel S; Lochs H Thalidomide for treatment of intestinal bleeding: Correlation to VEGF | 1 | 1 |
| 1334 | 0 | 0 | 1454 2002 APR [15] GASTROENTEROLOGY 122(4):A395-A395 Kim JW; Kim SG; Kim HD; Kim CG; Kim BG; Kim JS; Jung HC; Song IS Effect of DA-6034 and thalidomide on trinitrobenzene sulfonic acid-induced murine ileitis | 0 | 0 |
| 1335 | 0 | 0 | 1455 2002 APR [15] GASTROENTEROLOGY 122(4):A498-A498 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 0 | 0 |
| 1336 | 0 | 0 | 1457 2002 APR [15] GUT 50:A4-A4 Khan ZH; Simpson E; Cole AT; Macdonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: The effects of thalidomide on weight loss and lean body mass in a sequential (metabolic) study | 1 | 1 |
| 1337 | 13 | 20 | 1461 2002 APR [15] HAEMATOLOGICA 87(4):344-345 Ribatti D; Vacca A Is thalidomide a true anti-angiogenic molecule in multiple myeloma? | 1 | 1 |
| 1338 | 14 | 22 | 1462 2002 APR [15] HAEMATOLOGICA 87(4):345-346 [Anon] Inside Haematologica: caution in the use of thalidomide for treatment of hematologic disorders | 0 | 0 |
| 1339 | 15 | 35 | 1463 2002 APR [15] HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |
| 1340 | 27 | 44 | 1472 2002 APR [15] INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1341 | 39 | 67 | 1479 2002 APR-JUN [APR 15] JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
| 1342 | 4 | 5 | 1486 2002 APR 15 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
| 1343 | 4 | 17 | 1539 2002 APR [15] ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 5 | 6 |
| 1344 | 3 | 21 | 1544 2002 APR [15] PHARMACEUTICAL RESEARCH 19(4):434-439 Goosen C; Laing TJ; du Plessis J; Goosen TC; Lu GW; Flynn GL Percutaneous delivery of thalidomide and its N-alkyl analogs | 3 | 4 |
| 1345 | 0 | 83 | 1552 2002 APR [15] SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
| 1346 | 17 | 38 | 1526 2002 20020423-01:31:50 [APR 23] LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
| 1347 | 13 | 15 | 1496 2002 MAY 1 JOURNAL OF INFECTIOUS DISEASES 185(9):1359-1363 Wohl DA; Aweeka FT; Schmitz J; Pomerantz R; Cherng DW; Spritzler J; Fox L; Simpson D; Bell D; Holohan MK; Thomas S; Robinson W; Kaplan G; Teppler H; Natl Inst Allergy Infect Dis AIDS Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267 | 5 | 5 |
| 1348 | 1 | 3 | 1293 2002 MAY 7 ANNALS OF INTERNAL MEDICINE 136(9):711-711 Escudier B; Lassau N; Leborgne S; Angevin E; Laplanche A Thalidomide and venous thrombosis | 6 | 9 |
| 1349 | 30 | 71 | 1305 2002 MAY [15] BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
| 1350 | 50 | 93 | 1311 2002 MAY [15] BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1351 | 12 | 36 | 1400 2002 MAY [15] BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 13 | 23 |
| 1352 | 23 | 42 | 1495 2002 MAY 15 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
| 1353 | 0 | 0 | 1501 2002 MAY [15] JOURNAL OF NUCLEAR MEDICINE 43(5):267P-267P Kinuya S; Yokoyama K; Li XF; Bai J; Michigishi T; Tonami N Radioimmunotherapy with I-131-monoclonal antibody and antiangiogenic therapy with thalidomide in colon cancer xenografts. | 0 | 0 |
| 1354 | 102 | 164 | 1440 2002 20020521-02:50:07 [MAY 21] DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
| 1355 | 57 | 82 | 1432 2002 20030526-16:40:42 [MAY 26] CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
| 1356 | 5 | 5 | 1318 2002 JUN 1 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 13 | 18 |
| 1357 | 4 | 4 | 1319 2002 JUN 1 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
| 1358 | 3 | 6 | 1320 2002 JUN 1 BLOOD 99(11):4249-4249 Zangari M Thalidomide and thromboembolism - Response | 0 | 0 |
| 1359 | 20 | 24 | 1487 2002 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 20(11):2607-2609 Eisen T Thalidomide in solid malignancies | 6 | 12 |
| 1360 | 6 | 26 | 1488 2002 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1361 | 21 | 36 | 1283 2002 JUN [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 15 |
| 1362 | 9 | 36 | 1299 2002 JUN [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
| 1363 | 8 | 14 | 1302 2002 JUN 15 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 47(3):249-254 Huang F; Gu JR; Zhao W; Zhu J; Zhang JL; Yu DTY One-year open-label trial of thalidomide in ankylosing spondylitis | 3 | 11 |
| 1364 | 30 | 45 | 1312 2002 JUN [15] BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
| 1365 | 12 | 35 | 1321 2002 JUN 15 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 14 | 54 |
| 1366 | 0 | 0 | 1395 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S26-S26 Marriott JB; Clarke IA; Dredge K; Pandha H; Kristaleit H; Polychronis A; Muller GW; Stirling D; Dalgleish AG Thalidomide analogue CDC-501 is safe and well tolerated by patients with end stage cancer and shows evidence of clinical responses and extensive immune activation | 3 | 3 |
| 1367 | 0 | 0 | 1396 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S42-S42 Braybrooke JP; Madhusudan S; Blann A; Wilner S; Flanagan E; Jenkins A; Echeta C; Perren T; Ganesan TS Randomised phase two study of carboplatin versus carboplatin and thalidomide in patients with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. | 0 | 0 |
| 1368 | 0 | 0 | 1397 2002 JUN [15] BRITISH JOURNAL OF CANCER 86:S117-S118 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling D; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumour activity in which caspase dependent apoptosis is associated with altered expression of BCL-2 family proteins | 0 | 0 |
| 1369 | 4 | 6 | 1399 2002 JUN [15] BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
| 1370 | 4 | 5 | 1401 2002 JUN [15] BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1371 | 25 | 54 | 1425 2002 JUN [15] CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 14 | 15 |
| 1372 | 0 | 0 | 1430 2002 JUN [15] CLINICAL IMMUNOLOGY 103(3):S95-S95 Verastegui E; Morales R; Martinez R; Barrera J Immunological effects of thalidomide treatment of cancer patients. | 0 | 0 |
| 1373 | 58 | 107 | 1433 2002 JUN [15] CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
| 1374 | 0 | 0 | 1447 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):60-60 Biscardi M; Gavazzi S; Balestri F; Grossi A Angiogenic growth factors (VEGF, TGF-b1, bFGF) and thalidomide effect in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 1375 | 0 | 0 | 1448 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):98-98 Schey S; Jones R; Raj K; Streetley M A phase I study of an immunomodulatory thalidomide analogue (CC4047) in relapse/refractory multiple myeloma | 0 | 0 |
| 1376 | 0 | 0 | 1449 2002 JUN [15] EXPERIMENTAL HEMATOLOGY 30(6):98-98 Mohty M; Blaise D; Isnardon D; Olive D; Gaugler B Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide: implications for multiple myeloma therapy | 0 | 0 |
| 1377 | 10 | 19 | 1482 2002 JUN [15] JOURNAL OF CLINICAL MICROBIOLOGY 40(6):2302-2304 Curley MJ; Hussein SA; Hassoun PM Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma | 0 | 0 |
| 1378 | 3 | 16 | 1513 2002 JUN [15] JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
| 1379 | 5 | 23 | 1522 2002 JUN [15] LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
| 1380 | 7 | 17 | 1530 2002 20020629-02:12:34 [JUN 29] MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1381 | 3 | 3 | 1288 2002 JUL [15] AMERICAN JOURNAL OF HEMATOLOGY 70(3):265-265 Pulik M; Genet P; Lionnet F; Touahri T Thalidomide-associated gynecomasty in a patient with multiple myeloma | 1 | 1 |
| 1382 | 6 | 28 | 1294 2002 JUL [15] ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 12 | 23 |
| 1383 | 3 | 14 | 1295 2002 JUL [15] ANNALS OF ONCOLOGY 13(7):1116-1119 Alexanian R; Weber D; Giralt S; Delasalle K Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy | 7 | 10 |
| 1384 | 0 | 1 | 1300 2002 JUL [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(7):2313-2313 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis (vol 46, pg 1889, 2002) | 0 | 0 |
| 1385 | 4 | 4 | 1402 2002 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 1386 | 14 | 29 | 1420 2002 JUL [15] CHEST 122(1):227-232 Baughman RP; Judson MA; Teirstein AS; Moller DR; Lower EE Thalidomide for chronic sarcoidosis | 4 | 27 |
| 1387 | 8 | 16 | 1422 2002 JUL-AUG [JUL 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(4):S43-S44 Seyahi E; Ozdogan H; Masatlioglu S; Yazici H Successful treatment of familial Mediterranean fever attacks with thalidomide in a colchicine resistant patient | 0 | 4 |
| 1388 | 7 | 18 | 1450 2002 JUL [15] FARMACO 57(7):551-554 Blaschke G; Meyring M; Muhlenbrock C; Chankvetadze B Recent results of biotransformation of drugs: investigation of the in vitro biotransformation of thalidomide using a dual cyclodextrin system in capillary electrophoresis | 0 | 2 |
| 1389 | 12 | 38 | 1456 2002 JUL [15] GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 14 |
| 1390 | 11 | 22 | 1468 2002 JUL [15] INTERNATIONAL IMMUNOPHARMACOLOGY 2(8):1143-1153 Shannon EJ; Sandoval FG Thalidomide can costimulate or suppress CD4(+) cells' ability to incorporate [H-3]-thymidine-dependence on the primary stimulant | 4 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1391 | 19 | 30 | 1474 2002 JUL [15] INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE 6(7):569-572 Fu LM; Fu-Liu CS Thalidomide and tuberculosis | 2 | 3 |
| 1392 | 0 | 0 | 1497 2002 JUL [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(1):212-212 Heere-Ress E; Boehm J; Hoeller C; Thallinger C; Wolff K; Pehamberger H; Jansen B Anti-tumor effect of thalidomide and dacarbazine in melanoma SCID mouse model | 0 | 0 |
| 1393 | 0 | 1 | 1514 2002 SUM [JUL 15] JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1394 | 0 | 0 | 1533 2002 JUL-AUG [JUL 15] NEUROBIOLOGY OF AGING 23(1):S93-S93 Burke W; Bohac D; Cotter R; Zheng JL; Potter J; Gendelman H A 26 week double blind, placebo-controlled study of the efficacy of thalidomide in the treatment of Alzheimer's disease | 0 | 0 |
| 1395 | 11 | 15 | 1549 2002 JUL [15] REVUE DE MEDECINE INTERNE 23(7):651-656 Claudon A; Dietemann JL; De Compte AH; Hassler P Interest of thalidomide in cutaneo-mucous and hypothalamo-hypophyseal in Langerhans cell histiocytosis. | 1 | 1 |
| 1396 | 10 | 26 | 1435 2002 20020717-00:58:03 [JUL 17] DERMATOLOGY 204(4):365-367 Nijsten T; Meuleman L; Schroyens W; Lambert J Thalidomide-induced morbilliform rash: Diagnosis and continuation of therapy, premedicated with methylprednisolone | 0 | 0 |
| 1397 | 10 | 22 | 1506 2002 JUL 20 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 29(4):761-766 Liu T; Li MX; Li QY Electrochemical behavior of thalidomide | 0 | 0 |
| 1398 | 13 | 40 | 1291 2002 AUG 1 ANALYTICAL CHEMISTRY 74(15):3726-3735 Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites | 0 | 3 |
| 1399 | 1 | 1 | 1489 2002 AUG 1 JOURNAL OF CLINICAL ONCOLOGY 20(15):3361-3361 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial (vol 20, pg 2610, 2002) | 0 | 0 |
| 1400 | 4 | 23 | 1322 2002 AUG 15 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 19 | 33 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1401 | 1 | 3 | 1323 2002 AUG 15 BLOOD 100(4):1519-1520 Leleu X; Magro L; Fawaz A; Bauters F; Facon T; Yakoub-Agha I Efficacy of a low dose of thalidomide in advanced multiple myeloma | 7 | 7 |
| 1402 | 13 | 33 | 1411 2002 AUG 15 CANCER 95(4):758-765 Daliani DD; Papandreou CN; Thall PF; Wang XM; Perez C; Oliva R; Pagliaro L; Amato R A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma | 6 | 11 |
| 1403 | 1 | 9 | 1426 2002 AUG [15] CLINICAL CANCER RESEARCH 8(8):2750-2750 Go RS; Horstman AL Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. | 0 | 0 |
| 1404 | 0 | 6 | 1427 2002 AUG [15] CLINICAL CANCER RESEARCH 8(8):2751-2751 Neben K Correspondence re: K. Neben et al, High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7 : 2675-2681, 2001. Reply | 0 | 0 |
| 1405 | 5 | 25 | 1444 2002 AUG [15] EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
| 1406 | 3 | 10 | 1464 2002 AUG [15] HAEMATOLOGICA 87(8):884-886 Musto P; Falcone A; Sanpaolo G; Bisceglia M; Matera R; Carella AM Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes | 1 | 1 |
| 1407 | 10 | 15 | 1481 2002 AUG [15] JOURNAL OF CLINICAL GASTROENTEROLOGY 35(2):149-150 Kane S; Stone LJ; Ehrenpreis E Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab - A case series | 3 | 5 |
| 1408 | 6 | 28 | 1502 2002 AUG [15] JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
| 1409 | 2 | 32 | 1503 2002 AUG-SEP [AUG 15] JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 24(6):488-491 Soni S; Lee DS; DiVito J; Bui AH; DeRaffele G; Radel E; Kaufman HL Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide | 0 | 1 |
| 1410 | 7 | 15 | 1509 2002 AUG [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1411 | 10 | 18 | 1545 2002 AUG [15] PHARMACEUTICAL RESEARCH 19(8):1232-1235 Goosen C; Laing TJ; du Plessis J; Goosen TC; Rao TB; Flynn GL Chemical stabilities and biological activities of thalidomide and its N-alkyl analogs | 3 | 3 |
| 1412 | 11 | 47 | 1546 2002 AUG [15] PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
| 1413 | 8 | 11 | 1550 2002 AUG [15] REVUE DE MEDECINE INTERNE 23(8):724-727 Gachon J; Grob JJ; Richard MA Thalidomide treatment leading thrombotic events: two cases | 3 | 4 |
| 1414 | 0 | 0 | 1279 2002 AUG 18 ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 224:U21-U21 Hu ZG; Zink J; Zili X; Shi JD; Li PK Anti-angiogenic and anti-proliferative thalidomide analogs. | 0 | 0 |
| 1415 | 1 | 6 | 1529 2002 SEP 2 MEDICAL JOURNAL OF AUSTRALIA 177(5):278-278 McBride W Thalidomide and cancer | 1 | 1 |
| 1416 | 0 | 0 | 1515 2002 SEP 4 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
| 1417 | 80 | 118 | 1415 2002 20020905-05:14:02 [SEP 05] CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
| 1418 | 6 | 15 | 1280 2002 SEP [15] ACTA DERMATO-VENEREOLOGICA 82(5):384-386 Kolde G; Schulze P; Sterry W Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis | 1 | 2 |
| 1419 | 0 | 16 | 1285 2002 SEP [15] AMERICAN BIOLOGY TEACHER 64(7):495-500 Seidman LA; Warren NN Frances Kelsey & thalidomide in the US: A case study relating to pharmaceutical regulations | 0 | 0 |
| 1420 | 0 | 0 | 1287 2002 SEP 15 AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY 59(18):1700-+ Young D Thalidomide prescribers cannot assign survey responsibility to pharmacists | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1421 | 0 | 0 | 1303 2002 SEP [15] ARTHRITIS AND RHEUMATISM 46(9):S290-S290 Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GRV Thalidomide in lupus: Efficacy and toxicity are not dose-dependent. | 0 | 0 |
| 1422 | 0 | 0 | 1304 2002 SEP [15] ARTHRITIS AND RHEUMATISM 46(9):S480-S481 Schwartz KH; Agle LMA; Lehman TJA Thalidomide therapy of systemic onset JIA: Continued success. | 0 | 2 |
| 1423 | 3 | 33 | 1314 2002 SEP [15] BIOORGANIC & MEDICINAL CHEMISTRY 10(9):3067-3073 Lima LM; Castro P; Machado AL; Fraga CAM; Lugnier C; de Moraes VLG; Barreiro EJ Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues | 2 | 6 |
| 1424 | 3 | 20 | 1324 2002 SEP 15 BLOOD 100(6):2263-2265 Neben K; Mytilineos J; Moehler TM; Preiss A; Kraemer A; Ho AD; Opelz G; Goldschmidt H Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma | 10 | 21 |
| 1425 | 8 | 8 | 1325 2002 SEP 15 BLOOD 100(6):2272-2273 Cavo M; Zamagni E; Cellini C; Tosi P; Cangini D; Cini M; Valdre L; Palareti G; Masini L; Tura S; Baccarani M Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy | 11 | 15 |
| 1426 | 10 | 23 | 1414 2002 SEP [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 50(3):186-192 Ding Q; Kestell P; Baguley BC; Palmer BD; Paxton JW; Muller G; Ching LM Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide | 2 | 2 |
| 1427 | 75 | 130 | 1423 2002 SEP-OCT [SEP 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
| 1428 | 0 | 0 | 1452 2002 SEP [15] FERTILITY AND STERILITY 78(3):S87-S87 Scarpellini F; Sbracia M; Lecchini S; Scarpellini L Anti-angiogenesis treatment with thalidomide in endometriosis: A pilot study. | 0 | 1 |
| 1429 | 14 | 28 | 1476 2002 SEP [15] JAPANESE JOURNAL OF CANCER RESEARCH 93(9):1029-1036 Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y Thalidomide for the treatment of refractory multiple myeloma: Association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | 3 | 3 |
| 1430 | 0 | 0 | 1511 2002 SEP [15] JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1431 | 0 | 0 | 1512 2002 SEP [15] JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
| 1432 | 11 | 38 | 1518 2002 SEP [15] LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 8 | 13 |
| 1433 | 7 | 29 | 1523 2002 SEP [15] LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 1434 | 4 | 38 | 1532 2002 SEP [15] MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
| 1435 | 3 | 5 | 1540 2002 SEP [15] ONCOLOGY-NEW YORK 16(9):1146-+ Leibowitz R; Tucker SJ PSA response to thalidomide in patients with advanced prostate cancer | 0 | 0 |
| 1436 | 53 | 61 | 1541 2002 SEP [15] ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
| 1437 | 17 | 35 | 1553 2002 SEP [15] TERATOLOGY 66(3):115-121 Stromland K; Philipson E; Gronlund MA Offspring of male and female parents with thalidomide embryopathy: Birth defects and functional anomalies | 3 | 5 |
| 1438 | 0 | 0 | 1418 2002 OCT 7 CHEMICAL & ENGINEERING NEWS 80(40):60-60 [Anon] Thalidomide and Frances Kelsey | 0 | 0 |
| 1439 | 4 | 6 | 1296 2002 OCT [15] ANNALS OF ONCOLOGY 13(10):1636-1640 Grover JK; Uppal G; Raina V The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | 3 | 4 |
| 1440 | 18 | 27 | 1301 2002 OCT [15] ARCHIVOS DE BRONCONEUMOLOGIA 38(10):492-494 Valero FC; Gonzalez VB Lung toxicity due to thalidomide | 1 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1441 | 8 | 12 | 1403 2002 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 119(1):128-130 Wilson EA; Jobanputra S; Jackson R; Parker AN; McQuaker IG Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report | 1 | 3 |
| 1442 | 3 | 5 | 1404 2002 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 119(1):275-275 Pitini V; Teti D; Arrigo C; Aloi G Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF | 0 | 0 |
| 1443 | 6 | 43 | 1412 2002 OCT 15 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 15 |
| 1444 | 33 | 37 | 1421 2002 OCT [15] CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 17 | 19 |
| 1445 | 6 | 38 | 1437 2002 OCT [15] DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 3 |
| 1446 | 4 | 40 | 1477 2002 OCT [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
| 1447 | 16 | 34 | 1478 2002 OCT [15] JOURNAL OF CARDIAC FAILURE 8(5):306-314 Agoston I; Dibbs ZI; Wang F; Muller G; Zeldis JB; Mann DL; Bozkurt B Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure | 2 | 3 |
| 1448 | 3 | 5 | 1525 2002 OCT [15] LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
| 1449 | 2 | 25 | 1542 2002 OCT [15] PEDIATRIC RESEARCH 52(4):576-579 Narita N; Kato M; Tazoe M; Miyazaki K; Narita M; Okado N Increased monoamine concentration in the brain and blood of fetal thalidomide-and valproic acid-exposed rat: Putative animal models for autism | 0 | 3 |
| 1450 | 0 | 0 | 1547 2002 OCT [15] PHARMACOTHERAPY 22(10):1362-1362 Ando Y; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetics of thalidomide: drug response, in vivo metabolism and genetic polymorphism of CYP2C19. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1451 | 2 | 18 | 1419 2002 20021016-04:06:50 [OCT 16] CHEMICAL COMMUNICATIONS (19):2242-2243 Augusti DV; Augusti R; Carazza F; Cooks RG Quantitative determination of the enantiomeric composition of thalidomide solutions by electrospray ionization tandem mass spectrometry | 0 | 0 |
| 1452 | 0 | 0 | 1508 2002 20031024-09:12:41 [OCT 24] JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
| 1453 | 19 | 36 | 1445 2002 OCT 25 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
| 1454 | 21 | 37 | 1490 2002 NOV 1 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
| 1455 | 0 | 0 | 1469 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :104-104 Hatjiharissi E; Gerotziafas G; Papaioannou M; Bakaloudi V; Tokmaktsis A; Kaloutsi V; Christakis J; Zervas K Efficacy and tolerability of combination thalidomide-dexamethasone in multiple myeloma patients with refractory disease | 0 | 0 |
| 1456 | 0 | 0 | 1470 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :336-337 Chen LT; Chao Y; Yao TJ; Huang JD; Chang JY; Chin YH; Chuang TR; Reed E; Whang-Peng J; Liu TW Phase I and pharmacokinetic studies of oral thalidomide in advanced hepatocellular carcinoma | 0 | 0 |
| 1457 | 0 | 0 | 1471 2002 20021102-01:03:26 [NOV 02] INTERNATIONAL JOURNAL OF CANCER :402-402 Hatjiharissi E; Gerotziafas G; Hatjileontis C; Galaktidou G; Bakaloudi V; Papaioannou M; Kaloutsi V; Kortsaris A; Christakis J; Zervas K Study of neoangiogenesis and cytokine serum levels in patients with refractory multiple myeloma treated with thalidomide-dexamethasone | 0 | 0 |
| 1458 | 10 | 36 | 1398 2002 NOV 4 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 10 | 16 |
| 1459 | 13 | 27 | 1286 2002 NOV [15] AMERICAN HEART JOURNAL 144(5):847-850 Gullestad L; Semb AG; Holt E; Skardal R; Ueland T; Yndestad A; Froland SS; Aukrust P Effect of thalidomide in patients with chronic heart failure | 1 | 4 |
| 1460 | 11 | 27 | 1290 2002 NOV [15] AMERICAN JOURNAL OF MEDICINE 113(7):603-606 Bennett CL; Schumock GT; Desai AA; Kwaan HC; Raisch DW; Newlin R; Stadler W Thalidomide-associated deep vein thrombosis and pulmonary embolism | 3 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1461 | 0 | 4 | 1405 2002 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 119(2):576-577 Jones SG; Dolan G; Lengyel K; Myers B Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions | 0 | 3 |
| 1462 | 9 | 9 | 1407 2002 NOV [15] BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1303-1305 Eter N; Spitznas M DMSO mimics inhibitory effect of thalidomide on choriocapillary endothelial cell proliferation in culture | 0 | 0 |
| 1463 | 1 | 9 | 1408 2002 NOV [15] BRITISH JOURNAL OF OPHTHALMOLOGY 86(11):1315-1316 Shuttleworth GN; Cook SD; Ropner JE Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia | 0 | 0 |
| 1464 | 16 | 29 | 1413 2002 NOV-DEC [NOV 15] CANCER BIOLOGY & THERAPY 1(6):669-673 Ando L; Price DK; Dahut WL; Cox MC; Reed E; Figg WD Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide | 0 | 0 |
| 1465 | 14 | 18 | 1424 2002 NOV-DEC [NOV 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(6):S158-S161 Huang F; Wei JCC; Breban M Thalidomide in ankylosing spondylitis | 0 | 1 |
| 1466 | 17 | 24 | 1428 2002 NOV [15] CLINICAL CANCER RESEARCH 8(11):3377-3382 Neben K; Moehler T; Benner A; Kraemer A; Egerer G; Ho AD; Goldschmidt H Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma | 9 | 13 |
| 1467 | 33 | 53 | 1434 2002 NOV [15] CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
| 1468 | 3 | 34 | 1439 2002 NOV [15] DRUG NEWS & PERSPECTIVES 15(9):604-611 Botting J The history of thalidomide | 0 | 1 |
| 1469 | 0 | 0 | 1441 2002 NOV [15] EUROPEAN JOURNAL OF CANCER 38:S53-S53 Villalona-Calero M; Duan W; Otterson G; Kleiber B; Hindman K; Shah M; Young D; Wu W; Kuhn J Thalidomide modulation of Irinotecan; an NF-kB dependent effect? | 0 | 0 |
| 1470 | 0 | 0 | 1442 2002 NOV [15] EUROPEAN JOURNAL OF CANCER 38:S82-S82 Ng SSW; Kruger EA; Luzzio FA; Eger K; Guetschow M; Hauschildt S; Hecker T; Teubert U; Weiss M; Figg WD In vitro antiangiogenic activity of thalidomide analogues | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1471 | 13 | 15 | 1467 2002 NOV [15] HAUTARZT 53(11):744-748 Bohmeyer J; Achenbach A; Westenberger M; Stadler R Thalidomide therapy of cutaneous lupus erythematosus | 1 | 1 |
| 1472 | 7 | 20 | 1473 2002 NOV [15] INTERNATIONAL JOURNAL OF HEMATOLOGY 76(4):365-369 Miller S; Sharda S; Rodrigue J; Mehta P Thalidomide in chronic graft-versus-host disease after stem cell transplantation: Effects on quality of life | 0 | 0 |
| 1473 | 11 | 19 | 1475 2002 NOV [15] INVESTIGATIONAL NEW DRUGS 20(4):389-393 Minor DR; Monroe D; Damico LA; Meng G; Suryadevara U; Elias L A phase II study of thalidomide in advanced metastatic renal cell carcinoma | 7 | 10 |
| 1474 | 6 | 8 | 1498 2002 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988 Gaspari A Thalidomide neurotoxicity in dermatological patients: The next "STEP'' | 1 | 2 |
| 1475 | 17 | 24 | 1499 2002 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):1020-1026 Bastuji-Garin S; Ochonisky S; Bouche P; Gherardi RK; Duguet C; Djerradine Z; Poli F; Revuz J; Thalidomide Neuropathy Study Grp Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients | 9 | 12 |
| 1476 | 23 | 30 | 1500 2002 NOV [15] JOURNAL OF LEUKOCYTE BIOLOGY 72(5):939-945 Mohty M; Stoppa AM; Blaise D; Isnardon D; Gastaut JA; Olive D; Gaugler A Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide | 2 | 6 |
| 1477 | 20 | 32 | 1555 2002 NOV-DEC [NOV 15] THERAPIE 57(6):524-529 Boulin M; Blanchet F; Isambert N; Solary E; Solier S; Collin B; Pernot C; Durnet-Archeray MJ Role of thalidomide with or without dexamethasone for refractory multiple myeloma | 0 | 0 |
| 1478 | 0 | 0 | 1326 2002 NOV 16 BLOOD 100(11):15B-15B Carneiro JDA; Garanito M; Halsman M; Matsumoto L; Odone V; del Giglio A Thalidomide as salvage therapy for acquired severe aplastice anemia (SAA) in children - Case report | 0 | 0 |
| 1479 | 0 | 0 | 1327 2002 NOV 16 BLOOD 100(11):71A-71A Mesa RA; Li CY; Steensma DP; Pardanani A; Elliott MA; Kaufmann SH; Gray L; Schroeder GS; Tefferi A A combination of low dose thalidomide with prednisone in myelofibrosis with myeloid metaplasia. | 0 | 0 |
| 1480 | 0 | 0 | 1328 2002 NOV 16 BLOOD 100(11):75B-75B Kaushal V; Kaushal GP; Anaissie EJ; Kurylo P; Kohli M; Fink LM; Mehta P Thalidomide-induced coagulopathy: Evidence for an indirect effect on endothelium. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1481 | 0 | 0 | 1329 2002 NOV 16 BLOOD 100(11):96A-96A List AF; Kurtin SE; Glinsmann-Gibson BJ; Bellamy WT; Buresh AJ; Waddleton D; Knight R High erythropoietic remitting activity of the immunomodulatory thalidomide analog, CC5013, in patients with myelodysplastic syndrome (MDS). | 0 | 3 |
| 1482 | 0 | 0 | 1330 2002 NOV 16 BLOOD 100(11):96A-96A Moreno-Aspitia A; Geyer S; Li CY; Tefferi A; Witzig T; Niedrinhaus RD; Vukov AM; Morton R; Fitch T; Addo FE; Dakhil SR; Tschetter L; Colon-Otero G N998B: Multicenter phase II trial of thalidomide (Thal) in adult patients with myelodysplastic syndromes (MDS). | 0 | 1 |
| 1483 | 0 | 0 | 1331 2002 NOV 16 BLOOD 100(11):105A-105A Zangari M; Barlogie B; Prather J; Eddlemon P; Anaissie E; Lee CK; Tricot G; Thertulien R; van Rhee F Marked activity also in del 13 multiple myeloma (MM) of PS 341 (PS) and subsequent thalidomide (THAL) in a setting of resistance to post-autotransplant salvage therapies. | 0 | 5 |
| 1484 | 0 | 0 | 1332 2002 NOV 16 BLOOD 100(11):139A-139A List AF; Tate W; Glinsmann-Gibson BJ; Baker A The immunomodulatory thalidomide analog, CC5013, inhibits trophic response to VEGF in AML cells by abolishing cytokine-induced PI3-kinase/Akt activation. | 0 | 1 |
| 1485 | 0 | 0 | 1333 2002 NOV 16 BLOOD 100(11):162A-162A Drach J; Kaufmann H; Puespoek A; Bankier A; Urbauer E; Chott A; Raderer M Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma. | 0 | 1 |
| 1486 | 0 | 0 | 1334 2002 NOV 16 BLOOD 100(11):170A-170A Neben K; Mytilineos J; Kraemer A; Moehler TM; Preiss A; Ho AD; Opelz G; Goldschmidt H Thalidomide is able to improve the outcome in patients carrying the high producer haplotype of the interleukin-10 gene promoter in multiple myeloma. | 0 | 0 |
| 1487 | 0 | 0 | 1335 2002 NOV 16 BLOOD 100(11):178A-178A Brinker B; Waller EK; Langston AA; Redei I; Smith KJ; Bucur SZ; Winton E; Lyles R; Heffner LT; Lonial S Therapy with thalidomide enhances overall survival after autologous PBSC transplant for multiple myeloma. | 0 | 0 |
| 1488 | 0 | 0 | 1336 2002 NOV 16 BLOOD 100(11):209A-209A Weber D; Ginsberg C; Walker P; Obolendt M; Rankin K; Gavino M; Delasalle K; Alexanian R Correlation of thrombotic/embolic events (T/E) with features of hypercoagulability in previously untreated patients before and after treatment with thalidomide (T) or thalidomide-dexamethasone (TD). | 0 | 3 |
| 1489 | 0 | 0 | 1337 2002 NOV 16 BLOOD 100(11):210A-210A Barlogie B; Tricot G; Anaissie E; Fassas A; Lee CK; Thertulien R; van Rhee F; Zangari M Long-term follow-up (median of 4 yr) of 169 patients receiving thalidomide (THAL) for advanced and refractory multiple myeloma (MM): Superior survival in the absence of cytogenetic abnormalities (CA) and low beta-2 microglobulin (B2M). | 0 | 0 |
| 1490 | 0 | 0 | 1338 2002 NOV 16 BLOOD 100(11):211A-211A Palumbo A; Bertola A; Cavallo F; Falco P; Bringhen S; Giaccone L; Musto P; Pregno P; Boccadoro M Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma. | 0 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1491 | 0 | 0 | 1339 2002 NOV 16 BLOOD 100(11):211A-211A Myers B; Jones SG; McMillan AK; Dolan G Zoledronic acid, hypocalcaemia and renal dysfunction in thalidomide-treated myeloma patients. | 0 | 0 |
| 1492 | 0 | 0 | 1340 2002 NOV 16 BLOOD 100(11):265B-265B Manson SD; Gregory SA; Rogers K; Raza A; Loew J; Hsu WT; Sivaraman S; Venugopal P Thalidomide as a single agent leads to meaningful responses in older patients with poor prognosis acute myeloid leukemia (PP-AML) | 0 | 0 |
| 1493 | 0 | 0 | 1341 2002 NOV 16 BLOOD 100(11):314B-314B Hayashi T; Anderson KC; Steven SP Rituximab induced antibody dependent cell mediated cytotoxicity (ADCC) is enhanced by thalidomide and its analogue revimid. | 0 | 1 |
| 1494 | 0 | 0 | 1342 2002 NOV 16 BLOOD 100(11):336B-336B Musto P; Falcone A; Sanpaolo G; Bodenizza C; Bisceglia M; Matera R; Minervini MM; Carella AM Does thalidomide act with different mechanisms of action in myelodysplastic syndromes? | 0 | 0 |
| 1495 | 0 | 0 | 1343 2002 NOV 16 BLOOD 100(11):337B-337B Shetty V; Alvi S; Zorat F; Patkar S; Zahid S; Khan T; Mundle S; Galili N; Reddy P; Alvi M; Lisak L; Gezer S Effect of the anti-angiogenic agent thalidomide on the biological characteristics of patients with myelodysplastic syndromes. | 0 | 0 |
| 1496 | 0 | 0 | 1344 2002 NOV 16 BLOOD 100(11):340B-340B Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Bellak DJ; Gezer S; Venugopal P Combination of thalidomide and etanercept (Tumor necrosis factor receptor OR TNFR) effective in improving the cytopenias of some patients with myelodysplastic syndromes (MDS). | 0 | 2 |
| 1497 | 0 | 0 | 1345 2002 NOV 16 BLOOD 100(11):341B-341B Islam A; Bielat K; Smith G Does thalidomide have an effect other than anti-angiogenesis. | 0 | 0 |
| 1498 | 0 | 0 | 1346 2002 NOV 16 BLOOD 100(11):346B-346B Grossi A; Gavazzi S; Biscardi M; Balestri F; Bonsi L; Bagnara G; Pierdomenico L; Mazzucconi F Thalidomide therapy effects on angiogenic growth factors (VEGF, TGF-beta) and KDR expression in myeloid metaplasia with myelofibrosis. | 0 | 1 |
| 1499 | 0 | 0 | 1347 2002 NOV 16 BLOOD 100(11):367B-367B Luo SK; Li J; Hong WD; Zhou ZH Immunoreactivity of thalidomide in patients with multiple myeloma. | 0 | 0 |
| 1500 | 0 | 0 | 1348 2002 NOV 16 BLOOD 100(11):371B-371B Payvandi F; Wu L; Zhang LH; Muller G; Chen R; Stengel J; Harriri R; Stirling D Thalidomide and IMiDs inhibit microvessel formation from human arterial rings in the absence of human liver microsomes. | 0 | 0 |